Supernus Pharmaceuticals, INC 8-K filings

Supernus Pharmaceuticals and Indivior Pharmaceuticals have agreed to combine in an all-stock merger of equals to create a leading U.S. biopharma company focused on CNS diseases.

Supernus Pharmaceuticals and Indivior Pharmaceuticals announced a merger of equals to create a diversified CNS biopharmaceutical leader with significant scale and projected annual cost synergies of at least $125 million.

Supernus Pharmaceuticals announced strong Q2 2026 results with a 32% revenue increase and raised full-year guidance, alongside a significant all-stock merger of equals with Indivior Pharmaceuticals.

Supernus Pharmaceuticals and Indivior Pharmaceuticals announced a merger of equals to create a diversified CNS biopharmaceutical company, Supernus, Inc., with expected annual revenues of $2.2 billion and $125 million in cost synergies.

Supernus Pharmaceuticals announced its second quarter 2026 financial results will be released after market close on August 4, 2026, with a conference call to follow.

Supernus Pharmaceuticals, Inc. reported the results of its annual meeting of stockholders held on June 18, 2026, detailing votes on director elections, executive compensation, auditor ratification, and equity incentive plan amendments.

Supernus Pharmaceuticals announced the achievement of Milestone 1 under its Contingent Value Right Agreement, triggering a $33.4 million payment to CVR holders.

Supernus Pharmaceuticals reports a strong first quarter 2026 with a 39% revenue increase driven by its four growth products, reiterating full-year guidance.

Supernus Pharmaceuticals has announced it will report its first quarter 2026 financial results after market close on May 5, 2026.

Supernus Pharmaceuticals has entered into an Asset Purchase Agreement to acquire assets related to Navitor's compound NV-5138 (SPN-820), including intellectual property and clinical materials.

Supernus Pharmaceuticals, Inc. announced modifications to its executive officers' compensation, including salary increases, 2025 bonuses, and equity awards, effective January 1, 2026.

Supernus Pharmaceuticals announced record total revenues for the fourth quarter and full year 2025, driven by strong growth in its key products and strategic acquisitions.

Supernus Pharmaceuticals, Inc. announced it will report its fourth quarter and full year 2025 financial results on February 24, 2026, after market close.

Supernus Pharmaceuticals, Inc. has amended its 2018 merger agreement with Reich Consulting Group, Inc. to adjust the timing and payment of certain milestones.

Supernus Pharmaceuticals reported a 9% increase in Q3 2025 total revenues to $192.1 million, driven by strong growth products, and raised its full-year 2025 revenue guidance.

Supernus Pharmaceuticals announced it will report its third quarter 2025 financial and business results and host a conference call on November 4, 2025.

Supernus Pharmaceuticals completed its acquisition of Sage Therapeutics, integrating ZURZUVAE for postpartum depression, though pro forma financials show immediate losses.

Supernus Pharmaceuticals reported strong Q2 2025 sales for key growth products Qelbree and GOCOVRI, leading to an increased full-year revenue guidance despite a wider projected operating loss due to the Sage acquisition and higher expenses.

Supernus Pharmaceuticals, Inc. announced the appointment of Frank Mottola as Chief Technical Operations Officer, effective June 16, 2025, with a corresponding increase in his base salary and bonus target.

Supernus Pharmaceuticals has successfully completed its acquisition of Sage Therapeutics, integrating ZURZUVAE and a novel CNS discovery platform, with expected accretion in 2026 and up to $200 million in annual cost synergies.

Supernus Pharmaceuticals, Inc. announced it will report its second quarter 2025 financial and business results on Tuesday, August 5, 2025, followed by a conference call and webcast.

Supernus Pharmaceuticals, Inc. announced that its stockholders approved all proposals at the annual meeting held on June 16, 2025, including the re-election of two Class I directors, the non-binding approval of executive compensation, and the ratification of KPMG LLP as the independent auditor.

Supernus Pharmaceuticals, Inc. has entered into a definitive agreement to acquire Sage Therapeutics, Inc. for an upfront cash payment of $8.50 per share plus a contingent value right of up to $3.50 per share, aiming to strengthen its neuropsychiatry product portfolio with ZURZUVAE.

Supernus Pharmaceuticals, Inc. announced it received Paragraph IV Notice Letters from third parties seeking to market generic versions of its ADHD drug, Qelbree, prompting the company to vigorously defend its intellectual property rights.

Supernus Pharmaceuticals announces its first quarter 2025 financial results, highlighting a 4% increase in total revenues to $149.8 million and a 44% increase in Qelbree net sales.

Supernus Pharmaceuticals will release its Q1 2025 financial results after market close on May 6, 2025, followed by a conference call and webcast.

Supernus Pharmaceuticals announces positive financial results for Q4 and full year 2024, driven by significant growth in Qelbree sales and overall operating earnings, while also providing 2025 revenue guidance.

Supernus Pharmaceuticals has increased the base salaries and awarded bonuses and stock options to its executive officers, excluding the CEO, following a compensation committee review.

Supernus Pharmaceuticals announces that its Phase 2b study of SPN-820 for treatment-resistant depression did not achieve statistically significant improvement in depressive symptoms compared to placebo.

Supernus Pharmaceuticals will release its fourth quarter and full year 2024 financial results after market close on February 25, 2025, followed by a conference call and webcast.